Ideaya Biosciences, Inc. (NASDAQ: IDYA) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are initiating coverage of Ideaya with a Buy rating and $12 PT. Ideaya is a biotech company developing a pipeline of synthetically-lethality preclinical candidates, in addition to an in-licensed PKC inhibitor (IDE196|LXS196) from Novartis (NVS-NC) for the treatment of GNAQ|GNA11 mutant solid tumors. Data from a Phase 1/2 study of IDE196 is expected during 2Q|3Q 2020, and Ideaya's first syntheticallly lethal drug candidate should enter the clinic in 2H20. Below we highlight four reasons we like the set up.”
To request access to the full report, visit http://nnw.fm/DXCr3
About Ideaya Biosciences, Inc.
IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.